Blood‐based biomarkers for Alzheimer's disease
A Leuzy, N Mattsson‐Carlgren, S Palmqvist… - EMBO molecular …, 2022 - embopress.org
Neurodegenerative disorders such as Alzheimer's disease (AD) represent a mounting public
health challenge. As these diseases are difficult to diagnose clinically, biomarkers of …
health challenge. As these diseases are difficult to diagnose clinically, biomarkers of …
[HTML][HTML] The role of short-chain fatty acids from gut microbiota in gut-brain communication
YP Silva, A Bernardi, RL Frozza - Frontiers in endocrinology, 2020 - frontiersin.org
A substantial body of evidence supports that the gut microbiota plays a pivotal role in the
regulation of metabolic, endocrine and immune functions. In recent years, there has been …
regulation of metabolic, endocrine and immune functions. In recent years, there has been …
Association between sleep duration and cognitive decline
Importance An association between sleep duration and the trajectory of cognitive decline
has not been conclusively demonstrated. Objective To investigate the association between …
has not been conclusively demonstrated. Objective To investigate the association between …
Peptide-based vaccines: current progress and future challenges
RJ Malonis, JR Lai, O Vergnolle - Chemical reviews, 2019 - ACS Publications
Vaccines have had a profound impact on the management and prevention of infectious
disease. In addition, the development of vaccines against chronic diseases has attracted …
disease. In addition, the development of vaccines against chronic diseases has attracted …
[HTML][HTML] Inflammation as a central mechanism in Alzheimer's disease
JW Kinney, SM Bemiller, AS Murtishaw… - Alzheimer's & Dementia …, 2018 - Elsevier
Alzheimer's disease (AD) is a progressive neurodegenerative disorder that is characterized
by cognitive decline and the presence of two core pathologies, amyloid β plaques and …
by cognitive decline and the presence of two core pathologies, amyloid β plaques and …
Designing the next-generation clinical care pathway for Alzheimer's disease
The reconceptualization of Alzheimer's disease (AD) as a clinical and biological construct
has facilitated the development of biomarker-guided, pathway-based targeted therapies …
has facilitated the development of biomarker-guided, pathway-based targeted therapies …
Dementia prevention, intervention, and care: 2024 report of the Lancet standing Commission
Executive summary The 2024 update of the Lancet Commission on dementia provides new
hopeful evidence about dementia prevention, intervention, and care. As people live longer …
hopeful evidence about dementia prevention, intervention, and care. As people live longer …
APP mouse models for Alzheimer's disease preclinical studies
H Sasaguri, P Nilsson, S Hashimoto, K Nagata… - The EMBO …, 2017 - embopress.org
Animal models of human diseases that accurately recapitulate clinical pathology are
indispensable for understanding molecular mechanisms and advancing preclinical studies …
indispensable for understanding molecular mechanisms and advancing preclinical studies …
The economic burden of dementia in low-and middle-income countries (LMICs): a systematic review
Introduction More than two-thirds of people with dementia live in low-and middle-income
countries (LMICs), resulting in a significant economic burden in these settings. In this …
countries (LMICs), resulting in a significant economic burden in these settings. In this …
[HTML][HTML] Dual-drug loaded nanoparticles of Epigallocatechin-3-gallate (EGCG)/Ascorbic acid enhance therapeutic efficacy of EGCG in a APPswe/PS1dE9 Alzheimer's …
Abstract Epigallocatechin-3-gallate (EGCG) is a candidate for treatment of Alzheimer's
disease (AD) but its inherent instability limits bioavailability and effectiveness. We found that …
disease (AD) but its inherent instability limits bioavailability and effectiveness. We found that …